Works matching IS 01676997 AND DT 2018 AND VI 36 AND IP 6

Results: 21

Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 1110, doi. 10.1007/s10637-018-0685-7

By:

Roviello, Giandomenico;
Petrioli, Roberto;
Bonetta, Alberto;
Conca, Raffaele;
Rodriquenz, Maria Grazia;
Aieta, Michele

Publication type:

Article

Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 1158, doi. 10.1007/s10637-018-0679-5

By:

Goff, Laura W.;
Azad, Nilofer S.;
Stein, Stacey;
Whisenant, Jennifer G.;
Koyama, Tatsuki;
Vaishampayan, Ulka;
Hochster, Howard;
Connolly, Roisin;
Weise, Amy;
LoRusso, Patricia M.;
Salaria, Safia N.;
El-Rifai, Wael;
Berlin, Jordan D.

Publication type:

Article

A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 1103, doi. 10.1007/s10637-018-0672-z

By:

Yam, Clinton;
Murthy, Rashmi K.;
Rauch, Gaiane M.;
Murray, James L.;
Walters, Ronald S.;
Valero, Vicente;
Brewster, Abenaa M.;
Bast, Robert C.;
Booser, Daniel J.;
Giordano, Sharon H.;
Esteva, Francisco J.;
Yang, Wei;
Hortobagyi, Gabriel N.;
Moulder, Stacy L.;
Arun, Banu

Publication type:

Article

Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 1093, doi. 10.1007/s10637-018-0670-1

By:

Takahara, Naminatsu;
Nakai, Yousuke;
Isayama, Hiroyuki;
Sasaki, Takashi;
Saito, Kei;
Oyama, Hiroki;
Kanai, Sachiko;
Suzuki, Tatsunori;
Sato, Tatsuya;
Hakuta, Ryunosuke;
Ishigaki, Kazunaga;
Takeda, Tsuyoshi;
Saito, Tomotaka;
Mizuno, Suguru;
Kogure, Hirofumi;
Tada, Minoru;
Koike, Kazuhiko

Publication type:

Article

Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 1085, doi. 10.1007/s10637-018-0660-3

By:

Barata, Pedro C.;
Cooney, Matthew;
Mendiratta, Prateek;
Tyler, Allison;
Dreicer, Robert;
Garcia, Jorge A.

Publication type:

Article

Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 1072, doi. 10.1007/s10637-018-0658-x

By:

Tak, Won Young;
Ryoo, Baek-Yeol;
Lim, Ho Yeong;
Kim, Do-Young;
Okusaka, Takuji;
Ikeda, Masafumi;
Hidaka, Hisashi;
Yeon, Jong-Eun;
Mizukoshi, Eishiro;
Morimoto, Manabu;
Lee, Myung-Ah;
Yasui, Kohichiroh;
Kawaguchi, Yasunori;
Heo, Jeong;
Morita, Sojiro;
Kim, Tae-You;
Furuse, Junji;
Katayama, Kazuhiro;
Aramaki, Takeshi;
Hara, Rina

Publication type:

Article

Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 1116, doi. 10.1007/s10637-018-0624-7

By:

Wang, Chongchong;
Jing, Juehua;
Cheng, Li

Publication type:

Article

Design, synthesis and antiproliferative evaluation of novel sulfanilamide-1,2,3-triazole derivatives as tubulin polymerization inhibitors.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 1147, doi. 10.1007/s10637-018-0632-7

By:

Guo, Shewei;
Zhen, Yingwei;
Guo, Mengguo;
Zhang, Longzhou;
Zhou, Guosheng

Publication type:

Article

Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 1143, doi. 10.1007/s10637-018-0629-2

By:

Stump, Sarah E.;
Whang, Young E.;
Crona, Daniel J.

Publication type:

Article

Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 1138, doi. 10.1007/s10637-018-0628-3

By:

Kunimasa, Kei;
Isei, Taiki;
Nakamura, Harumi;
Kimura, Madoka;
Inoue, Takako;
Tamiya, Motohiro;
Nishino, Kazumi;
Kumagai, Toru;
Nakatsuka, Shin-ichi;
Endo, Hiroko;
Inoue, Masahiro;
Imamura, Fumio

Publication type:

Article

A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 1060, doi. 10.1007/s10637-018-0625-6

By:

Carducci, Michael;
Shaheen, Montaser;
Markman, Ben;
Hurvitz, Sara;
Mahadevan, Daruka;
Kotasek, Dusan;
Goodman, Oscar B.;
Rasmussen, Erik;
Chow, Vincent;
Juan, Gloria;
Friberg, Gregory R.;
Gamelin, Erick;
Vogl, Florian D.;
Desai, Jayesh

Publication type:

Article

Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 1133, doi. 10.1007/s10637-018-0653-2

By:

Sobhani, Navid;
Generali, Daniele;
D’Angelo, Alberto;
Aieta, Michele;
Roviello, Giandomenico

Publication type:

Article

Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 1044, doi. 10.1007/s10637-018-0601-1

By:

Hiret, Sandrine;
Isambert, Nicolas;
Gomez-Roca, Carlos;
Bennouna, Jaafar;
Sassi, Mouna;
de Mont-Serrat, Hélène;
Fan, Jean;
Schnell, David;
Delord, Jean-Pierre

Publication type:

Article

Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 1037, doi. 10.1007/s10637-018-0600-2

By:

Finn, R. S.;
Ahn, D. H.;
Javle, M. M.;
Tan, B. R.;
Weekes, C. D.;
Bendell, J. C.;
Patnaik, A.;
Khan, G. N.;
Laheru, D.;
Chavira, R.;
Christy-Bittel, J.;
Barrett, E.;
Sawyer, M. B.;
Bekaii-Saab, Tanios S.

Publication type:

Article

A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 1026, doi. 10.1007/s10637-018-0597-6

By:

Aung, Kyaw L.;
El-Khoueiry, Anthony B.;
Gelmon, Karen;
Tran, Ben;
Bajaj, Gaurav;
He, Bing;
Chen, Tian;
Zhu, Lili;
Poojary, Sharath;
Basak, Shashwati;
Qi, Zhenhao;
Spreafico, Anna;
Fischer, Bruce S.;
Desai, Jayesh

Publication type:

Article

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 1006, doi. 10.1007/s10637-018-0593-x

By:

de Vries Schultink, Aurelia H. M.;
Doornbos, Robert P.;
Bakker, Alexander B. H.;
Bol, Kees;
Throsby, Mark;
Geuijen, Cecile;
Maussang, David;
Schellens, Jan H. M.;
Beijnen, Jos H.;
Huitema, Alwin D. R.

Publication type:

Article

Acquired resistance to an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in an uncommon G719S EGFR mutation.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 999, doi. 10.1007/s10637-018-0592-y

By:

Osoegawa, Atsushi;
Hashimoto, Takafumi;
Takumi, Yohei;
Abe, Miyuki;
Yamada, Tomonori;
Kobayashi, Ryoji;
Miyawaki, Michiyo;
Takeuchi, Hideya;
Okamoto, Tatsuro;
Sugio, Kenji

Publication type:

Article

A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 1016, doi. 10.1007/s10637-018-0591-z

By:

Aghajanian, Carol;
Bell-McGuinn, Katherine M.;
Burris, Howard A.;
Siu, Lillian L.;
Stayner, Lee-Ann;
Wheler, Jennifer J.;
Hong, David S.;
Kurkjian, Carla;
Pant, Shubham;
Santiago-Walker, Ademi;
Gauvin, Jennifer L.;
Antal, Joyce M.;
Opalinska, Joanna B.;
Morris, Shannon R.;
Infante, Jeffrey R.

Publication type:

Article

New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 985, doi. 10.1007/s10637-018-0590-0

By:

Bigagli, Elisabetta;
Luceri, Cristina;
De Angioletti, Maria;
Chegaev, Konstantin;
D’Ambrosio, Mario;
Riganti, Chiara;
Gazzano, Elena;
Saponara, Simona;
Longini, Mariangela;
Luceri, Francesca;
Cinci, Lorenzo

Publication type:

Article

The molecular mechanism of anticancer action of novel octahydropyrazino[2,1-a:5,4-a′]diisoquinoline derivatives in human gastric cancer cells.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 970, doi. 10.1007/s10637-018-0584-y

By:

Pawłowska, Natalia;
Gornowicz, Agnieszka;
Bielawska, Anna;
Surażyński, Arkadiusz;
Szymanowska, Anna;
Czarnomysy, Robert;
Bielawski, Krzysztof

Publication type:

Article

Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells.

Published in:

Investigational New Drugs, 2018, v. 36, n. 6, p. 961, doi. 10.1007/s10637-018-0575-z

By:

Liu, Songlin;
Tang, Yunhong;
Yuan, Xianrui;
Yuan, Dun;
Liu, Junyu;
Li, Buyan;
Li, Yifeng

Publication type:

Article